Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nervousness19.06.02.003--Not Available
Neuromyopathy17.05.03.003; 15.05.03.0100.003542%Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurotoxicity17.02.10.002; 12.03.01.0110.002530%Not Available
Neutropenia01.02.03.004--Not Available
Neutrophil count13.01.06.046--Not Available
Nightmare19.02.03.0030.001518%Not Available
Non-Hodgkin's lymphoma16.35.01.001; 01.17.01.0010.001012%Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oesophageal varices haemorrhage24.07.02.022; 09.01.06.004; 07.12.01.0030.002024%
Opportunistic infection11.01.08.007--Not Available
Osteomalacia15.02.03.001; 20.01.01.002; 14.04.04.0010.003542%Not Available
Osteonecrosis24.04.05.004; 15.02.04.0070.001518%
Osteoporosis15.02.03.002; 14.04.04.0020.001518%
Osteosclerosis15.02.04.0120.001012%Not Available
Pain08.01.08.004--
Palpitations02.11.04.0120.003036%
Pancreatitis07.18.01.0010.001518%
Pancreatitis acute07.18.01.0020.001518%Not Available
Pancytopenia01.03.03.003--Not Available
Papule23.03.03.0380.001012%Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Pathological fracture16.32.03.007; 15.08.02.008; 12.04.02.0060.001518%Not Available
Peripheral sensory neuropathy17.09.03.005--
Pharyngitis22.07.03.004; 11.01.13.003; 07.05.07.004--
Phlebitis24.12.03.004; 12.02.01.002--
Photophobia17.17.02.006; 06.01.01.004--
Platelet count13.01.04.011--Not Available
Pleuritic pain22.12.01.0070.002024%
Pollakiuria20.02.02.007--
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages